drugset
drugset / Trial / NCT05252715

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

NCT05252715 ↗

Phase 3 Unknown 1200 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.

Timeline

Start
2021-12-18
Primary completion
2023-08-22
Completion
2024-09-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Meningococcal A and C Polysaccharide Conjugate Vaccine Vaccine 20 ug Intramuscular
Subject Meningococcal ACYW135 Polysaccharide Conjugate Vaccine Vaccine 20 ug Intramuscular

Indications

meningococcal meningitis